The Alzheimer’s Disease Cooperative Study (ADCS) was formed in 1991 as a cooperative agreement between the National Institute on Aging (NIA) and the University of California, San Diego. The ADCS is a major initiative for Alzheimer’s disease (AD) clinical studies in the Federal Government, addressing treatments for both cognitive and behavioral symptoms. The ADCS is part of the NIA Division of Neuroscience’s effort to facilitate the discovery, development and testing of new drugs for the treatment of AD and is part of the Alzheimer’s Disease Prevention Initiative as well.
CURRENT ADCS STUDIES
The Discover Study is a randomized, double-blind, placebo controlled study. Participants will be treated with a low, middle, or high dose of Posiphen, or a placebo.ADCS Response to COVID-19
The Alzheimer’s Disease Cooperative Study (ADCS) will remain open and operational and will continue to provide service to our partners and sites. Due to the evolving situation with COVID-19, and with the health of our ADCS staff and their families as our highest priority, all ADCS staff are currently on telework. We have made these adjustments to normal activities in order to increase social distancing in the workplace and in keeping with current public health directives and guidance. We expect some adjustments as we adapt to operating in these uncertain and rapidly changing times, so we appreciate your understanding and patience.